By The Creator Economy Editorial Team Editorial oversight by Ismail Oyekan Ismail Oyekan is the Editor-in-Chief of The Creator Economy and the founder of IMCX (Influencer Marketing Conference & Expo), the premier industry gathering connecting creators, brands, and capital
doi: 10.1016/S2213-8587(22)00085-7 136 NybergJJacobssonCAndersonMFErikssonPS
Laboratories that fail to maintain consistent storage conditions risk introducing variability into their experiments that can skew data and make replication difficult
Compounded retatrutide is a separate category and the FDA has issued public statements warning about online sellers using research-use labels
The premium over research peptide pricing reflects the regulatory infrastructure, prescriber consultations, and standardized compounding processes
Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor